Could vitamin C improve the therapeutic effect of integrated medicine for COVID-19?

Combined the therapy of Western medicine, traditional Chinese medicine, and a high dose of vitamin C resulted in the most effective outcome for flight against COVID-19. It’s shortening the time of disease recovery, symptom disappearance, chest CT improvement, and tongue amelioration. Traditional Chinese medicine such as Bai-Nu decoction, and Buzhong Yiqi decoction possessed anti-inflammatory, anti-oxidant properties, which improved the properties of western medicines added by increasing the white blood cell count and lymphocyte count supplement with vitamin C for combating COVID-19.The western medicines that are commonly used include (i) alpha-interferon (5 million U or equivalent dose each time for adults and twice daily), (ii) lopinavir/ritonavir (200 mg/50 mg per pill for adults, two pills each time and twice daily), ribavirin (jointly with interferon or lopinavir/ritonavir, 500 mg each time for adults, and twice or three times of intravenous injection daily), chloroquine phosphate (500 mg for 7 days, adults aged 18-65 with body weight over 50 kg), and arbidol (200 mg for adults, and no longer than 10 days). (To be continued)..

Could Artemisinin Increase the Sensitivity of Photodynamic Therapy Against SARS-CoV-2 Infection?

None

Multi-Wavelength Observations Of A New Redback Millisecond Pulsar 4FGL J1910.7-5320

We present the study of multi-wavelength observations of an unidentified Fermi Large Area Telescope (LAT) source, 4FGL J1910.7-5320, a new candidate redback millisecond pulsar binary. In the 4FGL 95% error region of 4FGL J1910.7-5320, we find a possible binary with a 8.36-hr orbital period from the Catalina Real-Time Transient Survey (CRTS), confirmed by optical spectroscopy using the SOAR telescope. This optical source was recently independently discovered as a redback pulsar by the TRAPUM project, confirming our prediction. We fit the optical spectral energy distributions of 4FGL J1910.7-5320 with a blackbody model, inferring a maximum distance of 4.1 kpc by assuming that the companion fills its Roche-lobe with a radius of R = 0.7R_sun. Using a 12.6 ks Chandra X-ray observation, we identified an X-ray counterpart for 4FGL J1910.7-5320, with a spectrum that can be described by an absorbed power-law with a photon index of 1.0+/-0.4. The spectrally hard X-ray emission shows tentative evidence for orbital variability. Using more than 12 years of Fermi-LAT data, we refined the position of the {\gamma}-ray source, and the optical candidate still lies within the 68% positional error circle. In addition to 4FGL J1910.7-5320, we find a variable optical source with a periodic signal of 4.28-hr inside the 4FGL catalog 95% error region of another unidentified Fermi source, 4FGL J2029.5-4237. However, the {\gamma}-ray source does not have a significant X-ray counterpart in a 11.7 ks Chandra observation, with a 3-{\sigma} flux upper limit of 2.4*10^-14 erg cm^-2 s^-1 (0.3-7 keV). Moreover, the optical source is outside our updated Fermi-LAT 95% error circle. These observational facts all suggest that this new redback millisecond pulsar powers the {\gamma}-ray source 4FGL J1910.7-5320 while 4FGL J2029.5-4237 is unlikely the {\gamma}-ray counterpart to the 4.28-hr variable.Comment: Accepted for publication in Ap

IACT observations of gamma-ray bursts: prospects for the Cherenkov Telescope Array

Gamma rays at rest frame energies as high as 90 GeV have been reported from gamma-ray bursts (GRBs) by the Fermi Large Area Telescope (LAT). There is considerable hope that a confirmed GRB detection will be possible with the upcoming Cherenkov Telescope Array (CTA), which will have a larger effective area and better low-energy sensitivity than current-generation imaging atmospheric Cherenkov telescopes (IACTs). To estimate the likelihood of such a detection, we have developed a phenomenological model for GRB emission between 1 GeV and 1 TeV that is motivated by the high-energy GRB detections of Fermi-LAT, and allows us to extrapolate the statistics of GRBs seen by lower energy instruments such as the Swift-BAT and BATSE on the Compton Gamma-ray Observatory. We show a number of statistics for detected GRBs, and describe how the detectability of GRBs with CTA could vary based on a number of parameters, such as the typical observation delay between the burst onset and the start of ground observations. We also consider the possibility of using GBM on Fermi as a finder of GRBs for rapid ground follow-up. While the uncertainty of GBM localization is problematic, the small field-of-view for IACTs can potentially be overcome by scanning over the GBM error region. Overall, our results indicate that CTA should be able to detect one GRB every 20 to 30 months with our baseline instrument model, assuming consistently rapid pursuit of GRB alerts, and provided that spectral breaks below 100 GeV are not a common feature of the bright GRB population. With a more optimistic instrument model, the detection rate can be as high as 1 to 2 GRBs per year.Comment: 28 pages, 24 figures, 4 tables, submitted to Experimental Astronom

Varicella vaccine dose depended effectiveness and waning among preschool children in Hong Kong.

In Hong Kong, universal varicella vaccination was introduced in July 2014 with a two-dose schedule but the vaccines had been available in the private market since 1996. With data from varicella notification and surveys on immunization coverage, we used the screening method to estimate dose-specific varicella vaccine effectiveness (VE) among preschool children in Hong Kong before universal vaccination. We estimated the VE of one- and two-dose varicella vaccination against all notified varicella as 69.4% (95% confidence interval (95% CI) 69.5-71.2) and 93.4% (95% CI 91.7-94.7), respectively. We found that VE did not decrease with time since receipt. Varicella vaccine was more effective against complications (85.4% [95% CI 48.8-95.8] for one dose and 100% [95% CI -Inf to 100] for two doses) and against hospital admission (75.2% [95% CI 53.4-86.8] for one dose and 93.1% [95% CI 47.1-99.1] for two doses). Lower protection of one-dose varicella vaccine resulted in breakthrough varicella. Under universal vaccination, second-dose varicella vaccine (given as combined measles, mumps, rubella and varicella vaccine) was first scheduled for children when they reach primary one (about 6 years of age) and was recently advanced to 18 months of age. Shortening the interval between the first dose and second dose of varicella vaccination should reduce breakthrough varicella and outbreaks in preschool

An ancient founder mutation in PROKR2 impairs human reproduction

Congenital gonadotropin-releasing hormone (GnRH) deficiency manifests as absent or incomplete sexual maturation and infertility. Although the disease exhibits marked locus and allelic heterogeneity, with the causal mutations being both rare and private, one causal mutation in the prokineticin receptor, PROKR2 L173R, appears unusually prevalent among GnRH-deficient patients of diverse geographic and ethnic origins. To track the genetic ancestry of PROKR2 L173R, haplotype mapping was performed in 22 unrelated patients with GnRH deficiency carrying L173R and their 30 first-degree relatives. The mutation's age was estimated using a haplotype-decay model. Thirteen subjects were informative and in all of them the mutation was present on the same ∼123 kb haplotype whose population frequency is ≤10%. Thus, PROKR2 L173R represents a founder mutation whose age is estimated at approximately 9000 years. Inheritance of PROKR2 L173R-associated GnRH deficiency was complex with highly variable penetrance among carriers, influenced by additional mutations in the other PROKR2 allele (recessive inheritance) or another gene (digenicity). The paradoxical identification of an ancient founder mutation that impairs reproduction has intriguing implications for the inheritance mechanisms of PROKR2 L173R-associated GnRH deficiency and for the relevant processes of evolutionary selection, including potential selective advantages of mutation carriers in genes affecting reproductio

Identification of the Bovine Arachnomelia Mutation by Massively Parallel Sequencing Implicates Sulfite Oxidase (SUOX) in Bone Development

Arachnomelia is a monogenic recessive defect of skeletal development in cattle. The causative mutation was previously mapped to a ∼7 Mb interval on chromosome 5. Here we show that array-based sequence capture and massively parallel sequencing technology, combined with the typical family structure in livestock populations, facilitates the identification of the causative mutation. We re-sequenced the entire critical interval in a healthy partially inbred cow carrying one copy of the critical chromosome segment in its ancestral state and one copy of the same segment with the arachnomelia mutation, and we detected a single heterozygous position. The genetic makeup of several partially inbred cattle provides extremely strong support for the causality of this mutation. The mutation represents a single base insertion leading to a premature stop codon in the coding sequence of the SUOX gene and is perfectly associated with the arachnomelia phenotype. Our findings suggest an important role for sulfite oxidase in bone development

Electromagnetic Wave Theory and Applications

Contains table of contents for Section 3, research summary and reports on six research projects.Joint Services Electronics Program (Contract DAAL 03-86-K-0002)Joint Services Electronics Program (Contract DAAL 03-89-C-0001)U.S. Navy - Office of Naval Research (Contract N00014-86-K-0533)National Science Foundation (Contract ECS 86-20029)U.S. Army Research Office (Contract DAAL03 88-K-0057)International Business Machine CorporationSchlumberger-Doll ResearchNational Aeronautics and Space Administration (Contract NAG 5-270)U.S. Navy - Office of Naval Research (Contract N00014-83-K-0258)National Aeronautics and Space Administration (Contract NAG 5-769)U.S. Army Corps of Engineers - Waterways Experimental Station (Contract DACA39-87-K-0022)Simulation TechnologiesU.S. Air Force - Rome Air Development Center (Contract F19628-88-K-0013)U.S. Navy - Office of Naval Research (Contract N00014-89-J-1107)Digital Equipment Corporatio

Distinct 'Immuno-Allertypes' of Disease and High Frequencies of Sensitisation in Non-Cystic-Fibrosis Bronchiectasis

Rationale: Allergic sensitization is associated with poor clinical outcomes in asthma, chronic obstructive pulmonary disease, and cystic fibrosis; however, its presence, frequency, and clinical significance in non–cystic fibrosis bronchiectasis remain unclear. Objectives: To determine the frequency and geographic variability that exists in a sensitization pattern to common and specific allergens, including house dust mite and fungi, and to correlate such patterns to airway immune-inflammatory status and clinical outcomes in bronchiectasis. Methods: Patients with bronchiectasis were recruited in Asia (Singapore and Malaysia) and the United Kingdom (Scotland) (n = 238), forming the Cohort of Asian and Matched European Bronchiectasis, which matched recruited patients on age, sex, and bronchiectasis severity. Specific IgE response against a range of common allergens was determined, combined with airway immune-inflammatory status and correlated to clinical outcomes. Clinically relevant patient clusters, based on sensitization pattern and airway immune profiles (“immunoallertypes”), were determined. Measurements and Main Results: A high frequency of sensitization to multiple allergens was detected in bronchiectasis, exceeding that in a comparator cohort with allergic rhinitis (n = 149). Sensitization was associated with poor clinical outcomes, including decreased pulmonary function and more severe disease. “Sensitized bronchiectasis” was classified into two immunoallertypes: one fungal driven and proinflammatory, the other house dust mite driven and chemokine dominant, with the former demonstrating poorer clinical outcome. Conclusions: Allergic sensitization occurs at high frequency in patients with bronchiectasis recruited from different global centers. Improving endophenotyping of sensitized bronchiectasis, a clinically significant state, and a “treatable trait” permits therapeutic intervention in appropriate patients, and may allow improved stratification in future bronchiectasis research and clinical trials.Ministry of Education (MOE)Ministry of Health (MOH)National Medical Research Council (NMRC)Published versionSupported by the Singapore Ministry of Health’s National Medical Research Council under its Transition Award NMRC/TA/0048/2016 (S.H.C.) and Changi General Hospital Research grant CHF2016.03-P (T.B.L.). The work performed at NUS was supported by the Singapore Ministry of Education Academic Research Fund, SIgN, and National Medical Research Council grants N-154-000-038-001, R-154-000-404-112, R-154-000-553-112, R-154-000-565-112, R-154-000-630-112, R-154-000-A08-592, R-154-000-A27-597, SIgN-06-006, SIgN-08-020, and NMRC/1150/2008 (F.T.C.); J.D.C. is supported by the GSK/British Lung Foundation Chair of Respiratory Research